Search company, investor...

Founded Year



Reverse Merger | IPO

Total Raised


Market Cap


Stock Price


About BenevolentAI

BenevolentAI (AMS: BAI) operates as a clinical-stage artificial intelligence (AI)-enabled drug discovery and development company. It uses its proprietary AI platform to identify and develop new drug candidates for a wide range of diseases such as cancer, Alzheimer's disease, and Parkinson's disease. The company was founded in 2013 and is based in Grand Duchy of Luxembourg, Luxembourg.

Headquarters Location

9 rue de Bitbourg L-1273

Grand Duchy of Luxembourg,


+44 (0)20 3781 9360


BenevolentAI's Products & Differentiators

    Target ID Collaboration

    Description: Maximise the opportunity to find novel drug targets for disease areas of interest, working with our cross-functional team of expert technologists, data scientists and drug discovery scientists


Research containing BenevolentAI

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned BenevolentAI in 6 CB Insights research briefs, most recently on Dec 12, 2022.

Expert Collections containing BenevolentAI

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

BenevolentAI is included in 3 Expert Collections, including Artificial Intelligence.


Artificial Intelligence

10,958 items

Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.


Digital Health

10,585 items

The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.


Drug Discovery Tech Market Map

221 items

This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.

BenevolentAI Patents

BenevolentAI has filed 42 patents.

The 3 most popular patent topics include:

  • machine learning
  • bioinformatics
  • biological databases
patents chart

Application Date

Grant Date


Related Topics




Clusters of differentiation, Cytokines, Inflammations, Transcription factors, Proteins


Application Date


Grant Date



Related Topics

Clusters of differentiation, Cytokines, Inflammations, Transcription factors, Proteins



Latest BenevolentAI News

Asset marketplace 9xchange augments toolbox with PhaseV trial analytics

Nov 16, 2023

Asset marketplace 9xchange augments toolbox with PhaseV trial analytics Second machine-learning partnership follows BenevolentAI deal in the spring By Paul Bonanos, Director of Biopharma Intelligence November 16, 2023 12:12 AM UTC As the user base grows for 9xchange’s asset marketplace, the company is continuing to add tools to help drug developers identify stalled programs that can reach the right set of patients. This month, the company announced a deal with PhaseV Trials Ltd. that will add machine learning-based clinical trials support tools to its marketplace. The partnership follows a spring 2023 agreement with BenevolentAI S.A. (Euronext:BAI), and figures to precede more deals, 9xchange Ltd. co-founder and CEO Anat Naschitz told BioCentury... BCIQ Company Profiles

BenevolentAI Frequently Asked Questions (FAQ)

  • When was BenevolentAI founded?

    BenevolentAI was founded in 2013.

  • Where is BenevolentAI's headquarters?

    BenevolentAI's headquarters is located at 9 rue de Bitbourg, Grand Duchy of Luxembourg.

  • What is BenevolentAI's latest funding round?

    BenevolentAI's latest funding round is Reverse Merger.

  • How much did BenevolentAI raise?

    BenevolentAI raised a total of $345.55M.

  • Who are the investors of BenevolentAI?

    Investors of BenevolentAI include Odyssey Acquisition, Tech Nation Fintech, Temasek, Woodford Investment Management, Lansdowne Partners and 4 more.

  • Who are BenevolentAI's competitors?

    Competitors of BenevolentAI include Oncocross, Aitia, Terray Therapeutics, Gero, Hexis Lab and 7 more.

  • What products does BenevolentAI offer?

    BenevolentAI's products include Target ID Collaboration and 2 more.

  • Who are BenevolentAI's customers?

    Customers of BenevolentAI include AstraZeneca.


Compare BenevolentAI to Competitors

Atomwise Logo

Atomwise develops machine learning-based discovery engines and uses deep learning and artificial intelligence (AI)-based neural networks to help discover new medicines. It predicts drug candidates for pharmaceutical companies, start-ups, and research institutions and designs drugs using computational drug design. The company was founded in 2012 and is based in San Francisco, California.

Insitro Logo

Insitro provides data-driven drug discovery and development solutions. It combines machine learning and modern biological tools to enable predictive models. The company was founded in 2018 and is based in South San Francisco, California.

Healx Logo

Healx provides drug discovery services. The company manufactures drugs using technology to bring treatments for rare diseases to patients. Its platform, Healnet, helps face challenges by analyzing drug and disease data points. The company was founded in 2014 and is based in Cambridge, U.K.

Aitia Logo

Aitia is a company focused on the development and application of Causal AI and Digital Twins in the pharmaceutical industry. The company's main services include the discovery of drugs for neurodegenerative disorders, oncology, and immunology by revealing hidden biological mechanisms of diseases and creating Digital Twins. These Digital Twins are used to discover novel therapies and accelerate research and development in various diseases such as Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease, multiple myeloma, prostate cancer, and pancreatic cancer. It was founded in 2000 and is based in Cambridge, Massachusetts.

Standigm Logo

Standigm is an AI-driven drug discovery company operating in the pharmaceutical industry. The company's main services include the use of proprietary AI platforms for novel target identification, lead generation, and the creation of commercially valuable drug pipelines. Standigm primarily sells to the pharmaceutical and healthcare industries. It was founded in 2015 and is based in Seoul, South Korea.

Aria Pharmaceuticals Logo
Aria Pharmaceuticals

Aria Pharmaceuticals is a preclinical-stage pharmaceutical company that focuses on the discovery and development of novel, small molecule therapies in the pharmaceutical industry. The company's main service is the development of new treatments for complex and hard-to-treat diseases using their proprietary Symphony platform, which combines biomedical data and artificial intelligence to increase the success rates of drug discovery. Aria Pharmaceuticals primarily serves the healthcare sector, specifically targeting areas where new therapies are most needed. It was founded in 2014 and is based in Palo Alto, California.


CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.